Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD: results from the FLAME study

被引：0
|
作者：
Fogel, Robert
Chapman, Kenneth R.
Vogelmeier, Claus F.
FowlerTaylor, Angel
Ayers, Tim
Thach, Chau
Whelan, Sarah
Clerkin, Karyn
Patalano, Francesco
Banerji, Donald
机构：
来源：
EUROPEAN RESPIRATORY JOURNAL | 2016年 / 48卷
关键词：
COPD; -; management; Bronchodilators; Treatments;
D O I：
10.1183/13993003.congress-2016.PA990
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA990
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥ 1 exacerbation in the previous year: The FLAME study
    Wedzicha, Jadwiga
    Vogelmeier, Claus F.
    Ayers, Tim
    FowlerTaylor, Angel
    Thach, Chau
    Olsson, Petter
    Fogel, Robert
    Patalano, Francesco
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [2] ONCE-DAILY INDACATEROL/GLYCOPYRRONIUM (IND/GLY) IS MORE EFFECTIVE THAN TWICE-DAILY SALMETEROL/FLUTICASONE (SFC) IN REDUCING EXACERBATIONS IN COPD PATIENTS AT A HIGH RISK OF EXACERBATIONS: THE FLAME STUDY
    Wedzicha, J. A.
    Chapman, K. R.
    Larbig, M.
    Patalano, F.
    Thach, C.
    Fogel, R.
    Banerji, D.
    RESPIROLOGY, 2016, 21 : 116 - 116
  • [3] Indacaterol/glycopyrronium (IND/GLY) is superior to salmeterol/fluticasone (SFC) in improving the health status of patients with moderate-to-very severe COPD: Results from the FLAME study
    Chapman, Kenneth R.
    Roche, Nicolas
    Ayers, Tim
    FowlerTaylor, Angel
    Thach, Chau
    Ahlers, Norbert
    Fogel, Robert
    Patalano, Francesco
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [4] SAFETY OF INDACATEROL/GLYCOPYRRONIUM (IND/GLY) COMPARED WITH SALMETEROL/FLUTICASONE (SFC) IN MODERATE-TO-VERY SEVERE COPD PATIENTS WITH PRIOR EXACERBATIONS: RESULTS FROM THE FLAME STUDY
    Wedzicha, J.
    Vestbo, J.
    Larbig, M.
    Fogel, R.
    Thach, C.
    Patalano, F.
    Banerji, D.
    RESPIROLOGY, 2016, 21 : 181 - 181
  • [5] INDACATEROL/GLYCOPYRRONIUM (IND/GLY) IS SUPERIOR TO SALMETEROL/FLUTICASONE (SFC) IN ASIAN PATIENTS WITH MODERATE-TO-VERY SEVERE COPD AT A HIGH RISK OF EXACERBATIONS: FLAME STUDY RESULTS
    Wedzicha, J. A.
    Zhong, N.
    Ichinose, M.
    Larbig, M.
    Humphries, M.
    Fogel, R.
    Thach, C.
    Patalano, F.
    Banerji, D.
    RESPIROLOGY, 2016, 21 : 180 - 180
  • [6] EFFICACY AND SAFETY OF ONCE-DAILY INDACATEROL/MOMETASONE COMPARED WITH TWICE-DAILY SALMETEROL/FLUTICASONE IN PATIENTS WITH MODERATE TO VERY SEVERE COPD
    Kirsten, Anne-Maria
    Richard, Alexia
    Tanase, Ana-Maria
    Cao Weihua
    Hosoe, Motoi
    Hederer, Bettina
    THORAX, 2014, 69 : A187 - A187
  • [7] INDACATEROL/GLYCOPYRRONIUM (IND/GLY) REDUCES THE RISK OF EXACERBATIONS VERSUS SALMETEROL/FLUTICASONE (SFC) IN MODERATE-TO-VERY SEVERE COPD PATIENTS IRRESPECTIVE OF PRIOR ICS/LABA/LAMA THERAPY: THE FLAME STUDY
    Wedzicha, Jadwiga A.
    Mezzi, Karen
    Ayers, Tim
    Thach, Chau
    Fogel, Robert
    Patalano, Francesco
    Banerji, Donald
    RESPIROLOGY, 2017, 22 : 84 - 84
  • [8] Cardiovascular (CV) safety of indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in moderate-to-very severe COPD patients with prior exacerbations: The FLAME study
    Roche, Nicolas
    Olsson, Petter
    Vestbo, Jorgen
    FowlerTaylor, Angel
    Ayers, Tim
    Thach, Chau
    Clerkin, Karyn
    Fogel, Robert
    Patalano, Francesco
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [9] Efficacy of Indacaterol/Glycopyrronium Versus Salmeterol/Fluticasone by Gender in Patients with Moderate-to-Very severe COPD: Analyses from the FLAME Study
    Wedzicha, J. A.
    Singh, D.
    Kostikas, K.
    Shen, S.
    Fogel, R.
    Fucile, S.
    Goyal, P.
    Mezzi, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [10] Respiratory safety profile of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC): results from the FLAME study
    Wedzicha, Jadwiga
    Vogelmeier, Claus F.
    Ayers, Tim
    Olsson, Petter
    Patalano, Francesco
    Thach, Chau
    Fogel, Robert
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
12345